April 13, 2017 / 11:27 AM / 5 months ago

Bristol-Myers to license two of its drugs to Biogen, Roche

April 13 (Reuters) - Bristol-Myers Squibb Co said on Thursday it entered into a deal with Biogen Inc and Roche Holding AG to license two of its drugs for an upfront fee of $470 million.

Bristol will license its experimental neurodegenerative disorder drug, BMS-986168, to Biogen for use in progressive supranuclear palsy, which is characterized by brain cell damage.

Bristol’s rare muscle-wasting disease drug, BMS-986089, will be licensed by Roche for use in duchenne muscular dystrophy. (Reporting by Akankshita Mukhopadhyay in Bengaluru; Editing by Maju Samuel)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below